Skip to main content

How does Aimovig work to prevent migraines?

Medically reviewed by Judith Stewart, BPharm. Last updated on Feb 1, 2024.

Official answer


Aimovig (erenumab-aooe) works by blocking the receptor of calcitonin gene-related peptide (CGRP) which is thought to contribute to the vasodilation and inflammation associated with migraine.

Aimovig is a fully human monoclonal antibody and is the first in the class of calcitonin gene-related peptide (CGRP) receptor antagonists for migraine prevention.

Aimovig is given once-a-month by subcutaneous (under the skin) self-injections with an auto-injector pen or a single-dose prefilled syringe.

Related medical questions

Drug information

Related support groups